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I. Abstract 
 
Leishmaniasis is a parasitic disease with a high incidence of infection 
and, in some cases, the potential to be fatal. This disease is largely 
entrenched in poverty, making access to effective and inexpensive 
diagnoses, treatments, and disease control unattainable for countless 
infected individuals.1 The need for affordable, more effective, and less 
toxic treatments has led us to the preparation and testing of plant 
extracts for screening against L. donovani parasites. Fractionation of the 
cones of a North American plant, found on The Ohio State University 
(OSU) campus and identified at the herbarium of The Ohio State 
University Museum of Biological Diversity as Taxodium distichum Rich. 
(Cupressaceae), commonly termed the bald cypress, has led to the 
observation of in vitro and in vivo activity against L. donovani. Previous 
studies have shown that abietane-type diterpenes, such as taxodione, 
taxodone, and taxodistines A and B are the major compounds present in 
the cones of T. distichum.2-4 These compounds have previously been 
reported to have antitumor, antimicrobial, and antileishmanial activity, 
but unfortunately have also been found to be accompanied by serious 
undesired toxicity.3-7 The purpose of this study was to isolate an 
antileishmanial compound or compounds from this plant source, which 
resulted in the purification and identification of taxoquinone and sugiol. 
Further fractionation is being conducted for the isolation and identification 
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of the particular chemical agent(s) responsible for the antileishmanial 
activity observed in the initial plant extract.  
 
II.  Introduction  
 
Leishmaniasis is a significant public health concern in at least 88 
countries worldwide, with approximately 12 million infected individuals.8 
Transmitted by an infected female sandfly vector, protozoan parasites of 
the genus Leishmania cause leishmaniasis via infiltration of tissue 
macrophages in host cells.1 Leishmaniasis has varying clinical 
manifestations including cutaneous leishmaniasis (CL), as characterized 
by skin lesions, and visceral leishmaniasis (VL), affecting the internal 
organs. VL, caused by L. donovani in particular, is the more serious 
variety of the disease because it is highly fatal if left untreated.1,8 The 
vast majority of leishmaniasis cases are concentrated in developing 
countries, with 90% of VL cases occurring in India, Bangladesh, Nepal, 
Sudan, and Brazil.1 Due to the absence of affluence among the majority 
of infected individuals, they often lack access to effective diagnosis and 
treatment. Additionally, current treatments are known to be accompanied 
by adverse side effects, ranging from nausea to serious cardiotoxicity.8 
Isolation of endemic populations in developing countries has also stifled 
funding for and efforts toward the discovery of more effective treatments, 
which is becoming a growing concern as Leishmania species continue to 
develop increasing drug resistance to the most commonly employed 
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treatments in modern medicine, for example, miltefosine, amphotericin B, 
and pentavalent antimonial compounds such as pentostam.1,8,9 Antimony 
is the first line of therapeutic action against leishmaniasis infections 
throughout the world, except in Bihar State in India, where the current 
cure rate in response to antimonial treatment has dropped to 
approximately 35%.1 The substantial resistance to therapy in Bihar 
highlights the need for alternative treatments. 
In addition to infecting approximately 1.5-2 million children and adults 
every year, leishmaniasis is associated with about 2.4 million disability-
adjusted life years (caused by enduring physical impairments and/or 
scarring that alters the lifestyles of the affected individuals) and 
approximately 70,000 deaths annually.1 Due to the high incidence of 
infection and the potential to be lethal, leishmaniasis has proven to be a 
pressing international health threat. There is a dense concentration of 
leishmaniasis cases in the Middle East, and the incidence of infection may 
be increasing there.10 Mainly due to its impact on military operations, 
leishmaniasis awareness is increasing in industrialized countries that 
would otherwise have no significant contact with or interest in the 
disease.11 United States military personnel have been affected during 
their service, with approximately 1300 cases of CL reported among 
individuals serving in Iraq and Afghanistan from 2003-2006.11 As 
leishmaniasis continues to affect more lives of individuals from all over 
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the globe, the need for innovative treatments is becoming increasingly 
urgent. 
III. Materials and Methods 
 
The cones of Taxodium distichum, shown in Figure 1, were previously 
found and collected with the help and permission of grounds-keeping staff 
of The Ohio State University (OSU), Columbus, OH, at and around Mirror 
Lake. T. distichum is a deciduous conifer capable of attaining heights of 
approximately 40 meters native to the southeastern region of North 
America. This specimen was planted specifically as an ornamental tree on 
the OSU campus.7,12  
 
Figure 1. T. distichum Cones 
The detannified chloroform-soluble extract of the cones was obtained 
by solvent partitioning after methanol percolation, utilizing polarity to 
attain fractions desired in accordance with the partitioning scheme 
described by Kupchan and coworkers and later modified by Wall et al., as 
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shown in Figure 2.13 Partial detannification was necessary because 
polyphenolic compounds such as tannins have a well-known reactivity 
towards proteins, often producing false positive results in bioassays, 
particularly those involving enzymes.13     
           Figure 2. Partitioning Scheme According to Wall et al.13 
The detannified chloroform-soluble extract of T. distichum cones 
(TDCD3) was tested against L. donovani promastigotes and found to be 
active, with IC50 = 2.1 μg/mL, supporting the proposed chromatographic 
fractionation to, ideally, purify and identify the observed leishmaniacidal 
agent(s). TDCD3 was applied to 40-63 μm normal-phase silica and 
separated with solvent systems of varying composition, based on polarity, 
by vacuum-liquid chromatography (VLC), as shown in Figure 3. VLC was 
Plant Material 
MeOH Extract 
Polar Residue Hexanes Extract 
 
Add H2O   
Partition with CHCl3 
CHCl3 Extract 
Detannified CHCl3 Extract 
(Test) 
Aqueous Extract 
 
Dissolve in mixture of MeOH-H2O (9:1) 
Defat with hexanes 
Wash with 1% NaCl 
Extract with MeOH 
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selected as the first means of separation in order to obtain an expedient and 
rapid set of subfractions. Due to the vacuum utilized, the separation may 
have been less efficient and precise than ideal, but this initial fractionation 
was useful for preliminary separation. Of the 14 fractions obtained, the 
second, termed TDCD3F2, displayed the only promising IC50 value after in 
vitro bioassay analysis against L. donovani, as shown in Table 1.  
 
 
Figure 3. Vacuum-Liquid Chromatography Apparatus14 
 
 
 
Table 1. In vitro Bioassay Results of TDCD3 VLC 
Subfractions 
                                 
Because TDCD3F2 exhibited the most potent inhibitory effect against L. 
donovani, it was selected for further fractionation. TDCD3F2 was also tested 
  Fractionation IC50 
  Elution from Silica 
by VLC 
Sample 
Weight (g) 
L. donovani 
promastigotes 
(µg/mL)   
TDCD3 25 g loaded 0.113 2.1* 
F2 25% EtOAc 13.706 < 5 
F3 25% EtOAc 2.361 > 10 
F4 50% EtOAc 2.156 > 10 
F5 50% EtOAc 0.843 > 50 
F6 50% EtOAc 0.475 > 50 
F7 75% EtOAc 0.657 > 50 
F8 EtOAc 0.304 > 50 
F9 EtOAc 0.105 < 100 
F10 25% MeOH 1.284 > 50 
F11 50% MeOH 0.355 > 25 
F12 MeOH 0.094 < 100 
F13 MeOH 0.053 > 50 
F14 H2O 0.652 > 100 
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in vivo in a murine model, and the results are shown in Figure 4.  TDCD3F2 
was tolerated in the mouse model and caused an observed dose-dependent 
decrease in liver and spleen parasite loads, further justifying further 
fractionation. This in vivo study was carried out by Dr. G. Gupta in the 
laboratory of Dr. A. R. Satoskar, Department of Pathology, Wexner Medical 
Center, OSU. 
 
Figure 4. In vivo Results of TDCD3 Against L. donovani in a Murine Model. Liver and 
Spleen Parasite Loads Shown Above, Respectively.  
 
Normal-phase 40-63 μm silica gel was utilized, and 7.1 g of TDCD3F2 
were loaded onto a chromatographic column, and varying solvent 
systems used in elution comprised of 10:1 hexane-ethyl acetate, 5:2 
hexane-ethyl acetate, and acetone, to elute the TDCD3F2 fraction 
through the silica matrix, relying only on gravity for this purpose. The 
eluates were collected in 104 separate sample tubes and analyzed by 
thin-layer chromatography (TLC) to determine those subfractions to 
 10 
combine into master pooled fractions based on similarities in their 
polarities, as shown in Figure 5.  
 
       Figure 5. TLC Profiles of Selected TDCD3F2 Subfractions 
 
Based on TLC results, the test tubes were combined into five pooled 
fractions, termed TDCD3F2.1 (comprised of fractions #1-19), TDCD3F2.2 
(comprised of fractions #20-32), TDCD3F2.3 (comprised of fractions #33-
51), TDCD3F2.4 (comprised of fractions #52-88), and TDCD3F2.5 
(comprised of fractions #89-104). A light yellow precipitate formed in the 
TDCD3F2.1 fraction, which was separated from the mother liquor of 
TDCD3F2.1, resulting in TDCD3F2.1p (for precipitate) and TDCD3F2.1m (for 
mother liquor). Moving forward, the TDCD3F2.1p fraction was not considered 
to be abundant enough to work up, but TDCD3F2.1m was. These five master 
fractions were tested in vitro against L. donovani promastigotes, with the 
results shown in Table 2.  
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In vitro Biological Activity Evaluation 
Transgenic DsRed2 Leishmania donovani promastigotes (expressing 
red fluorescent protein) were grown in Medium 199 substituted with 10% 
FBS and 1% penicillin and streptomycin. They were passaged infecting Stat-
4 KO mice (immunocompromised). 
Using a previously published procedure,15 L. donovani promastigotes 
as described above were placed into 24-well culture plates (1x106 
cells/mL/well) and exposed to different concentrations of drugs or test 
samples in duplicate for 72 hours at 23°C. Untreated promastigotes and 
those treated with 1 mg/mL saponin for 1 hour were kept as negative and 
positive controls, respectively, for the experiment. Miltefosine was used as a 
standard antileishmanial drug in this study. The drug-induced Leishmania 
killing was quantified by flow cytometry using a Fluorescence-Activated Cell 
Sorter (FACS). IC50 values (drug concentrations that resulted in 50% 
inhibition of parasite growth) were determined by GraphPad Prism® software 
using non-linear regression (Log inhibitor vs. Response on a variable slope).   
Identity IC50 (μg/mL) 
Miltefosine 1.8 
TDCD3F2.1m 0.8 
TDCD3F2.2 1.0 
TDCD3F2.3 1.9 
TDCD3F2.4 12.7 
TDCD3F2.5 >25 
Table 2. In vitro Bioassay Results for TDCD3F2 Subfractions 
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TDCD3F2.1m, TDCD3F2.2, and TDCD3F2.3 exhibited strong inhibitory 
activity against L. donovani, with TDCD3F2.1m and TDCD3F2.2 having IC50 
values lower than that of the miltefosine standard. TLC evaluation of these 
three potent fractions revealed similarities in their constituents, implying 
that they all could have contained the same active analyte(s). Since 
TDCD3F2.1m and TDCD3F2.2 were more potent than miltefosine and 
displayed the most similarities based on TLC analysis, shown in Figure 6, 
these two fractions were combined to produce TDCD3F2.1m2 in order to 
concentrate the potentially leishmaniacidal agent(s) and attempt isolation by 
further chromatographic separation and purification. Trace similarities were 
present in TDCD3F2.3, which could explain its biological activity, but there 
were more striking differences in its content according to TLC. In the interest 
of attempting to isolate the active agent, which seemed to be more 
concentrated in TDCD3F2.1m and TDCD3F2.2, TDCD3F2.3 was not combined 
with TDCD3F2.1m2 because its dissimilarities might have complicated the 
precise separation upon further work up.   
 
Figure 6. TLC Profiles of Bioactive Fractions 
TDCD3F2.1m (1) and TDCD3F2.2 (2) 
{ Location of Anticipated Bioactive Agents 
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 Approximately 4.2 g of TDCD3F2.1m2 were added to a glass column 
loaded with 40-63 μm normal-phase silica gel. Varying solvent systems 
comprised of 20:1 hexane-acetone, 10:1 hexane-acetone, and 5:2 hexane-
acetone were employed and the eluate(s) were collected to obtain a total of 
80 subfractions in separate test tubes.  Fractions #12-16 developed dark 
orange/brown crystals, shown in Figure 7, and fractions #42-47 developed 
light orange crystals without intervention.  The crystals resulting from #12-
16 were combined and purified by recrystallization in hexane/acetone to 
yield approximately 10 mg of bright orange crystals, shown in Figure 8, 
which were termed compound 1.  
          
             Figure 7. Crude Crystals of 1        Figure 8. Purified Crystals of 1 
 
Compound 1 was identified as taxoquinone by comparison of 400 MHz 
1H- and 100 MHz 13C-NMR spectroscopic data with previously published 
values.16,17 The crystals resulting from #42-47 were combined and purified 
by high-pressure liquid chromatography (HPLC) with a 77% methanol/23% 
water solvent method, yielding approximately 15 mg of white crystalline 
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solid after drying, termed compound 2. Compound 2 was identified as sugiol 
by comparison of NMR data with published values.18,19 The structure and 
NMR spectra of compound 1 are shown in Figures 9 and 10, while the 
structure and NMR spectra of compound 2 are shown in Figures 11 and 12.    
  
 
 
 
Figure 10. Taxoquinone 13C-NMR Spectrum (100 MHz, CDCl3) 
 
	
Figure 9. Taxoquinone Structure (left) and 1H-NMR 
Spectrum (below) 
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Figure 12. Sugiol 13C-NMR Spectrum (100 MHz, DMSO-d6) 
 
 
The 80 total fractions were analyzed by TLC and combined into nine 
master fractions: TDCD3F2.1m2-A (comprised of fractions #1-6), 
TDCD3F2.1m2-B (comprised of fractions #7-11), TDCD3F2.1m2-C 
(comprised of #12-19), TDCD3F2.1m2-D (comprised of fractions #20-24), 
	
Figure 11. Sugiol Structure (left) and 1H-NMR Spectrum 
(below) 
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TDCD3F2.1m2-E (comprised of fractions #25-33), TDCD3F2.1m2-F 
(comprised of #34-47), TDCD3F2.1m2-G (comprised of fractions #48-58), 
TDCD3F2.1m2-H (comprised of fractions #59-70), and TDCD3F2.1m2-I 
(comprised of fractions #71-80). Due to the limited availability of viable 
parasites necessary for biological activity evaluation, not all fractions could 
be tested in the bioassay. Compounds 1 and 2, and fractions C-G were 
tested in bioassay against L. donovani promastigotes utilizing the same 
procedure used for the previous set of fractions, set up shown in Figure 12. 
Results are shown in Table 3 and Figure 13. 
                
 
 
Identity IC50 (μg/mL) 
Miltefosine 1.8 
Compound 1 >25 
Compound 2 10.4 
TDCD3F2.1m2-C 2.1 
TDCD3F2.1m2-D 0.5 
TDCD3F2.1m2-E 0.5 
TDCD3F2.1m2-F 1.6 
TDCD3F2.1m2-G 1.9 
Table 3. In vitro Bioassay Results 
of TDCD3F2.1m2 Subfractions 
against L. donovani 
Promastigotes 
Figure 12. In vitro L. donovani 
Promastigote Bioassay Set Up 
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       Figure 13. Potent Inhibition of L. donovani by TDCD3F2.1m2-E 
 
IV. Conclusions 
 
The screening of Taxodium distichum cone subfractions has led to the 
identification of selected subfractions as samples possessing in vivo and in 
vitro leishmaniacidal utility, especially TDCD3F2.1m2-D and TDCD3F2.1m2-
E, which were significantly more potent than the reference drug miltefosine 
in vitro. The results also show that compounds 1 and 2 are inactive and 
weakly active against L. donovani promastigotes, respectively. As drug 
resistance becomes more prevalent among Leishmania species, the need for 
alternatives to current treatments is more pressing than ever before. The 
identification of lead compounds is crucial to the development of new 
therapies for pressing health issues such as leishmaniasis. With IC50 values 
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lower than those of some other treatments currently being employed, the T. 
distichum constituent(s) in question that produce the activity of the tested 
active fractions could qualify as lead compound(s) for drug development. 
However, further purification and more in vivo toxicology evaluation of these 
compounds must be completed before this could be tested in a human 
system. Also, tentative results from in vitro intracellular amastigote analysis 
exhibited marked decreases in observed potency against L. donovani, 
implying that there could be complications interacting with the amastigote 
developmental stage and/or with the ability to efficiently cross biological 
membranes to infiltrate infected cells. Moving forward, more precise 
fractionation by HPLC of the subfractions is necessary to isolate and later 
identify the agent(s) responsible for the antileishmanial character of those 
active subfractions. Natural products hold incalculable potential to counteract 
disease, which is why their investigation should be continued in an effort to 
identify other promising leads with potential to be developed into therapeutic 
agents, aiding in the global fight against leishmaniasis and other infectious 
diseases. 
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